Qube Research & Technologies (QRT)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.8M	Buy	930,631 +56,286	+6%	+$823K	0.02%	1090
2025 Q4	$13.9M	Sell	874,345 -278,500	-24%	-$3.95M	0.01%	1124
2025 Q3	$12.7M	Sell	1,152,845 -89,667	-7%	-$979K	0.01%	1168
2025 Q2	$10.5M	Buy	1,242,512 +386,364	+45%	+$3.1M	0.01%	1263
2025 Q1	$6.88M	Buy	856,148 +660,389	+337%	+$5.35M	0.01%	1363
2024 Q4	$1.76M	Buy	+195,759	New	+$1.6M	﹤0.01%	1936
2024 Q2	–	Sell	-172,153	Closed	-$862K	–	3799
2024 Q1	$862K	Buy	+172,153	New	+$1.17M	﹤0.01%	2233
2023 Q4	–	Sell	-71,378	Closed	-$555K	–	4327
2023 Q3	$555K	Buy	+71,378	New	+$698K	﹤0.01%	1983
2023 Q1	–	Sell	-17,545	Closed	-$75.8K	–	2529
2022 Q4	$75.8K	Buy	+17,545	New	+$102K	﹤0.01%	2064
2022 Q2	–	Sell	-111,809	Closed	-$1.38M	–	2481
2022 Q1	$1.38M	Buy	+111,809	New	+$1.73M	0.01%	1000

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AUPH Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Aurinia Pharmaceuticals (AUPH) stake by 6.4% in Q1 2026, buying an estimated $823K and bringing the position to 930,631 shares worth $13.8M. The position accounts for 0.02% of the portfolio, ranked #1090.

Qube Research & Technologies (QRT) first reported a position in AUPH in Q1 2022 and has held it in 10 quarters since. The position peaked at $13.9M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Qube Research & Technologies (QRT) held 930,631 shares of Aurinia Pharmaceuticals worth $13.8M as of Q1 2026.
Qube Research & Technologies (QRT) bought 56,286 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $823K.
Aurinia Pharmaceuticals made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1090 holding.
Qube Research & Technologies (QRT) first reported a position in Aurinia Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
Qube Research & Technologies (QRT)'s Aurinia Pharmaceuticals position peaked at $13.9M in Q4 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.